Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

@article{Williams2013ImmunotherapyTI,
  title={Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.},
  author={Emily L. Williams and Alison L. Tutt and Stephen A Beers and Ruth R. French and Claude H. T. Chan and Kerry Cox and Ali Roghanian and Christine A. Penfold and Ch{\'e}rie L. Butts and P{\'e}ter Boross and J. Sjef Verbeek and Mark S Cragg and Martin J. Glennie},
  journal={Journal of immunology},
  year={2013},
  volume={191 8},
  pages={4130-40}
}
Genetic deficiency of the inhibitory Fc receptor, FcγRIIB (CD32b), has been shown to augment the activity of activatory FcγR and promote mAb immunotherapy. To investigate whether mAbs capable of blocking FcγRIIB have similar capacity, we recently generated a panel of specific anti-mouse FcγRIIB mAbs that do not cross-react with other FcRs, allowing us to study the potential of FcγRIIB as a therapeutic target. Previous work revealed a number of these mAbs capable of eliciting programmed cell… CONTINUE READING